Work

Targeting Akt in cell transfer immunotherapy for cancer

Year: 2015

Type: article

Abstract: Pharmacologic inhibitors of the serine/threonine kinase Akt, initially aimed at deranged oncogenic pathways in tumors, have recently been shown to act as immunomodulators that markedly enhance the antitumor properties of T cells. Repurposing Akt inhibitors to improve antitumor immunity may be viewed as a manifestation of a larger paradigmatic shift in which hallmark characteristics of cancer (e.g., immune evasion), rather than merely causal features (e.g., somatic mutations) can be exploited for therapeutic benefit.

Source: OncoImmunology

DOI: 10.1080/2162402x.2015.1014776

Authors: Joseph G Crompton, Madhusudhanan Sukumar, Nicholas P Restifo

Institutions: National Institutes of Health, University of California, Los Angeles, National Cancer Institute

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $2,913